Inside the research
DaVita Inc.
DVA Research profile · latest available data
Price overview
$178.47
▲ +3.80 (+2.2%)
| 52w hi | $240.96 |
|---|---|
| 52w lo | $103.87 |
| Vol | 519.80K |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.11
| Short | -0.15 |
|---|---|
| Medium | +0.21 |
| Long | +0.42 |
computed 2026-09-27
Key fundamentals
DaVita Inc.
Healthcare · Medical Care Facilities
| Market cap | $11.39B |
|---|---|
| Enterprise value | $25.95B |
| Trailing P/E | 15.12x |
| Forward P/E | 10.41x |
| EV / EBITDA | 9.18x |
| P / S (ttm) | 0.82x |
| Profit margin | 6.0% |
| Return on equity | 88.5% |
| Revenue growth | +5.2% |
| Earnings growth | +55.8% |
| Debt / equity | 1241.99 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.32 | |
| Sector | +0.08 | |
| Technical | -0.07 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
Risk Metrics
| Beta vs SPX | 0.34 |
|---|---|
| Corr SPX | 0.14 |
| Annual vol | 39.7% |
| Annual ret | +11.9% |
| Sharpe | 0.30 |
| Max DD | -41.4% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $185.57 |
|---|---|
| High / Low | $235.00 / $144.00 |
| Median | $194.00 |
| Analysts | 7 |
| Strong Buy | 0 | |
|---|---|---|
| Buy | 2 | |
| Hold | 4 | |
| Sell | 0 | |
| Strong Sell | 2 |
Recent rating actions
| 2026-05-08 | Truist Securities | → Hold |
| 2026-05-08 | Barclays | → Equal-Weight |
| 2026-05-07 | UBS | → Buy |
| 2026-05-06 | Deutsche Bank | → Buy |
| 2026-02-04 | UBS | → Buy |
| 2026-02-03 | Barclays | → Equal-Weight |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-04 | Earnings Release, Exhibits | read |
| 2026-06-08 | Material Agreement, Material Obligation… | read |
| 2026-05-05 | Earnings Release, Exhibits | read |
| 2026-02-02 | Earnings Release, Exhibits | read |
| 2025-11-25 | Material Agreement, Material Obligation… | read |
| 2025-10-29 | Earnings Release, Exhibits | read |
| 2025-08-20 | Other Material Event | read |
| 2025-08-05 | Earnings Release, Exhibits | read |
| 2025-07-17 | Material Agreement, Material Obligation… | read |
| 2025-06-09 | Shareholder Vote | read |
| 2025-05-23 | Material Agreement, Material Obligation… | read |
| 2025-05-20 | Other Material Event, Exhibits | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-16 | Rodriguez Javier | Chief Executive Officer | Sell | 39.41K | $8.25M |
| 2026-06-15 | Rodriguez Javier | Chief Executive Officer | Sell | 30.00K | $6.29M |
| 2026-06-15 | Waters Kathleen Alyce | Chief Legal & Pub. Affair | Sell | 6.46K | $1.35M |
| 2026-06-15 | Waters Kathleen Alyce | Chief Legal & Pub. Affair | Sell | 8.95K | $1.86M |
| 2026-05-26 | YALE PHYLLIS R | Gift | 5.04K | — | |
| 2026-05-15 | YALE PHYLLIS R | Grant | 250 | — | |
| 2026-05-15 | DESOER BARBARA J | Grant | 250 | — | |
| 2026-05-15 | Pullin Dennis W | Grant | 250 | — | |
| 2026-05-15 | Moore Gregory J. | Grant | 250 | — | |
| 2026-05-15 | Schoppert Wendy Lee | Grant | 250 | — |
Flow & Concentration
| Insider 180d net | -$17.74M |
|---|---|
| Insider buys / sells | 0 / 4 |
| Insider bias | Sellers |
| 13F holders | 10 |
| Top-5 share | 98.9% |
| HHI | 8,159 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| Berkshire Hathaway | $6.43B | 28.88M |
| State Street Corp | $294.35M | 1.32M |
| AQR Capital Management | $128.13M | 587.76K |
| Citadel Advisors | $100.93M | 453.66K |
| Capital Research / Capital World | $96.13M | 432.10K |
| Millennium Management | $49.63M | 223.09K |
| Fidelity / FMR LLC | $25.48M | 114.51K |
| Bridgewater Associates | $2.45M | 11.00K |
| Renaissance Technologies | $1.42M | 6.40K |
| T. Rowe Price Group | $22.75K | 102.27K |
As of 2026-06-30
SEC Filings
The Long Run
FY 2009–2025 · 17 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $13.64B | +3.5% | |
| Operating income | $2.09B | +5.7% | |
| Net income | $936.34M | +5.4% | |
| Cash from ops | $2.06B | +8.4% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $175.38 | $179.10 | $174.67 | $178.47 | 519.80K |
| Sep 24 | $183.10 | $183.78 | $174.32 | $174.67 | 812.40K |
| Sep 23 | $184.03 | $186.23 | $182.48 | $183.14 | 544.30K |
| Sep 22 | $184.01 | $185.85 | $182.94 | $183.72 | 552.50K |
| Sep 21 | $184.47 | $185.00 | $182.03 | $182.34 | 565.00K |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →